{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-142278","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.243762+00:00","generated_at":"2026-06-01T13:57:47.043108+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024","bullets":["Acquisition of Alpine for approximately $5.0B in equity value completed.","Alpine now operates as a wholly owned subsidiary of Vertex.","Accounting treatment for the acquisition to be finalized during Q2 2024.","Merger effected via tender offer followed by a Section 251(h) merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-142278","json":"https://secwatch.observer/filing/0001193125-24-142278.json","markdown":"https://secwatch.observer/filing/0001193125-24-142278.md","text":"https://secwatch.observer/filing/0001193125-24-142278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/0001193125-24-142278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000119312524142278/d818729d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:57:47.043108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}